Necsa

What Necsa does

Necsa (South African Nuclear Energy Corporation SOC Ltd) is a state-owned nuclear research, development, and technology corporation established under the Nuclear Energy Act of 1999 and wholly owned by the Republic of South Africa. The group is headquartered at the Pelindaba nuclear research site west of Pretoria and operates the 20 MW SAFARI-1 light-water research reactor — in continuous use since 1965 — together with the planned Multi-Purpose Reactor (MPR), the Beam Line Centre (neutron diffraction, imaging, MPISI, PITSI, MIXRAD, NRAD), the OSCAR-5 training reactor, an analytical and calibration laboratory, an ASME III-certified advanced manufacturing capability, a Technology Commercialisation Office, and the Necsa Learning Academy. Two wholly-owned subsidiaries extend the commercial reach: NTP Radioisotopes, ranked among the top four global producers of medical radioisotopes (Molybdenum-99, I-131, Lutetium-177), and Pelchem, which produces specialty fluoride chemicals.

The group derives revenue from medical radioisotope production and export (approximately 50% of revenue, primarily through NTP), nuclear professional services to Eskom including Koeberg long-term operation support, advanced nuclear-grade manufacturing of specialised equipment to post-Fukushima standards, research and beam-line services for industry, mining, and academia, plus technology transfer and licensing. The go-to-market is institutional: direct enterprise and government sales for isotope and services contracts, multi-year negotiated contracts with no publicly disclosed pricing, and international distribution of radiopharmaceutical products via NTP. Necsa is executing a R50 billion, six-programme expansion plan covering fuel-cycle re-establishment, SMR deployment, SAFARI-1 life extension, MPR construction, Pelchem/NTP expansion, and skills development, underpinned by R1.2 billion in secured government funding for MPR detailed design. FY2025 financial results showed R125.2 million net profit with 93% achievement against the Shareholder Compact and clean group audits.

Name

Necsa

Legal name

South African Nuclear Energy Corporation SOC Ltd

Website

https://necsa.co.za

Company type

Public

Founded year

1999

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Necsa is South Africa's state-owned nuclear research corporation, operating the SAFARI-1 reactor and subsidiaries NTP Radioisotopes and Pelchem to produce medical isotopes, provide nuclear professional services, and develop fuel-cycle and SMR technologies for healthcare, Eskom, and African markets.

Ownership category

akta.pro rank

Product category

Nuclear energy and radioisotope research services

NAICS

Irradiation Apparatus Manufacturing (334517)

SIC

X-Ray Apparatus & Tubes & Related Irradiation Apparatus (3844), Special Industry Machinery, Nec (3559), Measuring & Controlling Devices, Nec (3829)

akta.pro primary industry

Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.) (EUAKAIAA)

akta.pro secondary industries

Nuclear Materials Testing, Assay & Characterization Services (NDA/NDE, radiochemistry, materials analysis) (EUAKAIAL), Radionuclide Supply Chain & Logistics (Shielding/Transport/Distribution) (HLAIAGAH), IAEA Safeguards Implementation & Verification Support (inspections, declarations, reporting) (EUAKAJAE), Radioisotope Production (Reactor/Cyclotron/Gamma) (HLAIAGAD), Sealed Source Manufacturing, Encapsulation & Recycling/Take-Back (Source lifecycle management) (EUAKAIAI)

Keywords

• Nuclear research services
• Medical radioisotope production
• Nuclear reactor operations
• Radiopharmaceutical manufacturing
• Nuclear-grade equipment fabrication

Headquarters

HQ city

Pretoria

HQ country

South Africa

HQ region

Africa

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Infrastructure, Technology or R&D, Operations, Supply Chain

Revenue model

1. Medical Radioisotope Production and Sales: Production and global export of medical radioisotopes including Molybdenum-99, I-131, and Lutetium-177 through subsidiary NTP Radioisotopes; generates significant foreign currency and approximately 50% of company revenue
2. Radiopharmaceutical Products: Manufacturing of active pharmaceutical ingredients (APIs) for diagnosis and treatment of serious illnesses and cancers, exported in bulk as input material for radiopharmaceutical products
3. Nuclear Professional Services: Professional nuclear services including assistance for Koeberg long-term operation programme, equipment manufacturing, waste disposal, and technical expertise for nuclear industry
4. Nuclear Manufacturing: Advanced manufacturing of nuclear-grade equipment and specialized components; only ASME III certified company in Africa; produces pipes to post-Fukushima standards
5. Research and Development Services: Beam line research services, neutron activation analysis, material modification and testing, neutron non-destructive testing facilities for industry, mining, and academia
6. Technology Transfer and Licensing: Commercialisation of IP, technology transfer, licensing agreements, and innovation ecosystem cultivation through Technology Commercialisation Office

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Necsa operates nuclear research reactors (SAFARI-1 and the planned Multi-Purpose Reactor) to produce medical radioisotopes and provide nuclear-related services. It supplies Molybdenum-99, Iodine-131, and Lutetium-177 globally through subsidiary NTP Radioisotopes, and delivers nuclear-grade manufacturing, beam line research, waste management, and skills development services to government, healthcare, industrial, and academic clients.

Product overview

Necsa is a state-owned nuclear research corporation operating as a platform of interconnected research facilities, manufacturing capabilities, and subsidiaries. The core offering centers on the SAFARI-1 research reactor and the planned Multi-Purpose Reactor for radioisotope production and neutron research. Two primary subsidiaries extend the portfolio: NTP Radioisotopes handles nuclear medicine production (radiopharmaceuticals), while Pelchem produces specialty chemicals. Additional offerings include the Beam Line Centre for materials analysis, analytical laboratory services, advanced nuclear manufacturing (ASME III certified), nuclear waste management, the OSCAR-5 training reactor, and technology commercialisation services. The Necsa Learning Academy provides skills development. The company operates under a hub-and-spoke model where the research reactor facilities serve as the foundation for isotope production, manufacturing, and training services.

Differentiator

Problem solved

Functional benefit

Products and services

• SAFARI-1 Research Reactor A 20 MW light water-cooled research reactor at Pelindaba used for research and production of medical radioisotopes including Molybdenum-99, I-131, and Lutetium-177 for global export and domestic healthcare.
• Multi-Purpose Reactor (MPR) A planned industrial-scale reactor to replace SAFARI-1 with higher production capacity for radioisotopes, research through beam lines, and neutron scattering applications, featuring a cold neutron source and Neutron Beam Line Centre.
• NTP Radioisotopes A wholly-owned Necsa subsidiary and one of the top four global producers of nuclear medicine, producing and exporting radiopharmaceutical products including Molybdenum-99, I-131, and Lutetium-177 for medical diagnostics and cancer treatment.
• Pelchem (Necsa Chemicals)
• Beam Line Centre
• OSCAR-5 Training Reactor
• Analytical and Calibration Laboratory
• Advanced Manufacturing
• Nuclear Liabilities Management
• Necsa Learning Academy
• Technology Commercialisation
• Good Manufacturing Practice (GMP) Facility

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Twelve partnerships are on record, tiered core, major and minor.

• University of PretoriacoreStrategic or Co-development Partner · 23 June 2026MoU signed to establish bilateral cooperation in nuclear research, technology innovation, education, and skills development. Aims to develop South Africa's next generation of nuclear scientists, engineers, and professionals in support of the country's nuclear programme under IRP 2025. CEO Loyiso Tyabashe stated collaboration will unlock innovative solutions for economic growth, industrialisation, and sustainable development.
• Siemens EnergymajorStrategic or Co-development Partner · 17 June 2026MoU signed for collaboration on energy, innovation, and technology advancement. Establishes framework for cooperation focusing on energy technology and innovation initiatives between the two organisations.
• Sibanye-StillwatercoreStrategic or Co-development Partner · 17 April 2026Research collaboration to advance development of radioactive palladium isotope derived from rhodium for use in Targeted Radionuclide Therapy for cancer treatment. Necsa will test and verify rhodium for radionuclide production standards and carry out chemical processes to produce high-purity Pd-103.
• Rosatom (Russia)coreStrategic or Co-development Partner · 5 March 2026MoU signed at Africa Energy Indaba 2026 for nuclear skills development and human capital development. Advances strategic partnership and cooperates on workforce and labour market initiatives in the nuclear sector.
• ASP Isotopes / Quantum Leap EnergycoreStrategic or Co-development Partner · 20 February 2026Pre-Implementation Services Contract for siting, design, construction, and operation of HALEU enrichment facility at Necsa's Pelindaba site. Leverages QLE's proprietary enrichment technology with Necsa's nuclear infrastructure to advance commercial HALEU production for next-generation fission reactors. Projected HALEU demand: 50 metric tons/year by 2035, 500 metric tons/year by 2050.
• Energy and Water Sector Education and Training Authority (EWSETA)minorStrategic or Co-development Partner · 28 July 2025MoU signed to bolster South Africa's nuclear energy and water skills pipeline. Collaboration on skills development programmes to build future-ready workforce in energy landscape.
• Council for Scientific and Industrial Research (CSIR)coreStrategic or Co-development Partner · 23 April 2025MoU signed to collaborate on research and technology development initiatives. Seeks to synergize research capabilities of two State-owned organisations. Collaboration areas include modernizing manufacturing, agriculture, mining, digital and circular economy, health innovation, and energy innovation.
• China National Nuclear Corporation (CNNC)coreStrategic or Co-development Partner · 8 April 2025MoU signed during ministerial visit for cooperation in nuclear fuel cycle, SMRs, and other agreed-upon areas. Aims to advance negotiations of mutually beneficial cooperation in nuclear fuel cycle and SMR technology for African market entry.
• Korea Electric Power Corporation (Kepco)majorStrategic or Co-development Partner · 1 April 2025MoU signed for cooperation in South Africa's new nuclear power projects. Kepco keen to participate in South Africa's nuclear expansion plans.
• TVEL Fuel Company (Rosatom)coreStrategic or Co-development Partner · 27 July 2023MoU signed for cooperation in nuclear fuel production and related components. Both companies aim to share existing expertise and develop necessary capabilities. Signed on margins of 2nd Russia-Africa Summit. Paves way for Necsa to re-establish nuclear fuel production capability.
• Chemical Industries Education and Training Authority (CHIETA)minorStrategic or Co-development Partner · 31 March 2022MoU signed for collaboration on skills development programmes to assist in alleviating unemployment, especially amongst youth in South Africa.
• Korea Atomic Energy Research Institute (KAERI)majorStrategic or Co-development Partner · 13 October 2021MoU for Technical Cooperation covering nuclear technology, medical isotopes production, fluorine-based chemicals, and Human Resource management. Includes exchange of information, joint R&D, and collaboration on Zirconium-89 based radiopharmaceuticals for early cancer detection. Effective for five years from signing.

Scale indicators9 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• Australian Nuclear Science and Technology Organisation (ANSTO): Australian federal nuclear research organisation operating the OPAL research reactor and producing Mo-99 and other medical isotopes through ANSTO Health. Closest functional analogue to Necsa: state-owned research reactor operator, global medical isotope exporter, with beam line and nuclear manufacturing capabilities.
• SCK CEN (Studiecentrum voor Kernenergie / Centre d'Étude de l'Énergie Nucléaire): Belgian nuclear research centre operating the BR2 research reactor, one of the world's principal Mo-99 producers. Directly comparable to Necsa in mission (research, isotope production, materials testing) and in scale of medical isotope supply.
• NRG (Nuclear Research and Consultancy Group): Netherlands-based nuclear research operator of the HFR reactor at Petten, a major global producer of medical isotopes including Mo-99. Directly comparable to Necsa's SAFARI-1/NTP operations: reactor-based isotope production for global healthcare markets.
• Institute of Nuclear Chemistry and Technology (INCT) / POLATOM: Polish national nuclear research institute operating in concert with the Maria research reactor for medical isotope production including Mo-99 and Lu-177. Same mandate and revenue mix as Necsa/NTP: state-mandated nuclear research plus global radiopharmaceutical supply.
• Curium Pharma: Global nuclear medicine manufacturer covering Mo-99, I-131 and Lu-177 supply across multiple reactor partnerships. Directly competes with NTP Radioisotopes for downstream radiopharmaceutical customers in international markets.

Broad incumbents

• IAEA (International Atomic Energy Agency): UN-affiliated nuclear body that sets safeguards and nuclear research standards, of which Necsa is a partner and through which Necsa operates the AFCONE Regional Collaborating Centre. Comparable in mission scope (global nuclear cooperation, safeguards) though not a commercial competitor.
• Korea Atomic Energy Research Institute (KAERI): Korean state nuclear R&D institute with active MoU cooperation with Necsa. Operates research reactors and pursues SMR/HALEU-adjacent R&D with a similar state-mandate research-and-technology model, but with a much larger national nuclear programme.
• Rosatom: Russian state atomic energy corporation and active Necsa partner (MoUs via TVEL for fuel cycle and skills development). Comparable in being a state-owned full-scope nuclear corporation spanning fuel, reactors and isotopes, but vastly larger in scope and revenue.

Emerging players

• NorthStar Medical Radioisotopes: US-based producer developing non-reactor and reactor-based Mo-99 supply to reduce reliance on legacy reactors. Emerging competitor to NTP Radioisotopes in global Mo-99 markets, with technology and licensing that could pressure incumbent producers like Necsa.
• ASP Isotopes / Quantum Leap Energy: US- and South Africa-based isotope and HALEU enrichment company with an active Pre-Implementation Services Contract with Necsa at Pelindaba. Material emerging counterpart in Necsa's HALEU programme and a partial overlap in isotope production strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/necsa_ltd

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Necsa